The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
REGULATORY
MHLW Panel OKs List of “High-Priority” Vaccines, including Norovirus Jabs
A Japanese health ministry panel on March 13 approved a list of “vaccines of high development priority” deemed highly necessary for public health that should be developed on a priority basis and eventually incorporated into the national immunization program (NIP).…
To read the full story
Related Article
- MHLW Panel Finalizes NIP Inclusion of Shingles Jabs, OKs New Basic Immunization Plan
January 30, 2025
- Japan’s Redefinition of “High-Priority” Vaccines Likely to Speed Up Discussions on NIP Access
January 27, 2025
- MHLW Set to Redefine “Vaccines of High Development Priority” in New Plan
September 27, 2024
- Expedite Introduction of High-Priority Vaccines into National Schedule: Trade Groups
May 25, 2023
- MHLW to Resume Discussions on Revising Basic Immunization Plan
March 27, 2023
REGULATORY
- MHLW Council OKs Public Knowledge Filing for Anaemetro’s Pediatric Use
March 17, 2025
- PMDA Reviewing Safety Risks of Paxlovid/Xtandi Concurrent Use
March 17, 2025
- MHLW Panel OKs List of “High-Priority” Vaccines, including Norovirus Jabs
March 14, 2025
- JPA Asks for Price Penalty for High-Cost Meds with Packaging Unaligned to Dosing
March 14, 2025
- Chuikyo to Discuss Potential Pricing Steps to Deal with Higher Costs of Japan-Made APIs
March 13, 2025
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…